Advance of anti-atherosclerosis mechanism of sodium-glucose cotransporter 2 inhibitor
CHEN Jun
LIN Yuan
TANG Feng
Abstract：One of the leading causes of death globally is atherosclerotic cardiovascular disease(ASCVD),whose exact mechanism is yet unknown.Large-scale cardiovascular research recently demonstrated that sodium glucose cotransporter 2 inhibitors(SGLT-2i)can not only effectively lower the blood sugar in patients with type 2 diabetes but also significantly lower the risk of cardiovascular adverse events in the patients with ASCVD.As a result,SGLT-2i has emerged as a crucial medication for the treatment of both high-risk type 2 diabetes and ASCVD.SGLT-2i can also improve the quality of life and prognosis of patients,reduce the incidence and mortality of ASCVD,and show potential anti-atherosclerotic effects.This article reviews the recent progress of SGLT-2i in anti-atherosclerosis,and looks forward to the future research direction.
Keywords：Sodium-glucose cotransporter 2 inhibitorAtherosclerosisMetabolic syndromeInflammationOxidative stressAutophagy
Publication Date：2025-03-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 273-278 )